Strata Critical Medical (SRTA) EBIT Margin (2020 - 2026)

Strata Critical Medical has disclosed EBIT Margin across 7 years of filings, most recently posting 4.41% for Q1 2026.

• In Q1 2026, EBIT Margin rose 1140.0% year-over-year to 4.41%; the TTM figure through Mar 2026 stood at 7.85% (up 964.0% YoY), while the FY2025 annual figure was 11.34%, up 400.0% from the prior year.
• EBIT Margin rose to 4.41% in Q1 2026, from 9.59% in the prior quarter.
• Over the last five years, EBIT Margin for SRTA reached as high as 4.41% in Q1 2026 and fell as low as 75.05% in Q4 2023.
• The 5-year median for EBIT Margin is 17.88% (2024), against an average of 22.25%.
• The widest YoY moves for EBIT Margin: up 5883 bps in 2024, down 924 bps in 2024.
• A 5-year view of EBIT Margin shows it stood at 27.31% in 2022, then sank by 175 bps to 75.05% in 2023, then surged by 78 bps to 16.23% in 2024, then soared by 41 bps to 9.59% in 2025, then jumped by 54 bps to 4.41% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 4.41%, 9.59%, and 11.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.